Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-HER2-CAR-T cell
- Development stage
- Unknown
- Lead developer
- Baylor College of Medicine
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Injection, Transfusion
01
Overview
Anti-HER2-CAR-T cell therapy is a type of adoptive cell immunotherapy where a patient's T lymphocytes are genetically engineered to express a Chimeric Antigen Receptor (CAR) specifically designed to recognize and bind to the Human Epidermal Growth Factor Receptor 2 (HER2) protein. HER2 is a receptor tyrosine kinase often overexpressed on the surface of various solid tumor cells, including those found in breast, gastric, ovarian, colorectal, and lung cancers. Upon administration, these modified T-cells identify and target HER2-positive cancer cells, leading to their destruction and eliciting an anti-tumor immune response. This therapeutic approach aims to overcome the limitations of conventional therapies by providing a highly specific and potent cellular attack against HER2-expressing malignancies.
- Other names
- HER2 CAR-THER-2 CAR-THER 2 CAR-Tanti-HER2 CAR-Tanti-HER-2 CAR-Tanti-HER 2 CAR-THER2-specific CAR-THER-2-specific CAR-THER 2-specific CAR-T
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on anti-HER2-CAR-T cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-HER2-CAR-T cell.